Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | suspended | Phase 2 / Phase 3 | 150 | Mirror Biologics, Inc.INDUSTRY | 2 | Oct 23, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract | terminated | Phase 2 | 13 | American Regent, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06789757 | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)((HCC)) | recruiting | Phase 2 | 19 | Inova Health Care ServicesOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT03044587 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer(NIFE) | completed | Phase 2 | 93 | AIO-Studien-gGmbHOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05052099 | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer(COMBATBIL) | completed | Phase 1 / Phase 2 | 20 | University Hospital, EssenOTHER | 2 | Sep 29, 2025 | clinicaltrials |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | recruiting | Phase 2 | 33 | Yongyi ZengOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06467799 | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07192848 | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | not yet recruiting | Phase 2 | 47 | Song PengOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07187284 | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 62 | Zhongda HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07034950 | Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation | active not recruiting | Phase 1 / Phase 2 | 79 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06999694 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Proton-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04264260 | Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | completed | Phase 2 | 42 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07157306 | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03037437 | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | completed | Phase 2 | 64 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154082 | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 27 | Wei ZhangOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06902389 | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07151326 | Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy(CAPIO) | not yet recruiting | Phase 2 | 60 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07150377 | A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 41 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT07135544 | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | recruiting | Phase 2 | 37 | Yongjun ChenOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07129018 | Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer | not yet recruiting | Phase 2 | 63 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT03638141 | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | completed | Phase 2 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07100392 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-02) | recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)(TASK-05) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07128251 | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | not yet recruiting | Phase 2 | 47 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma(PEHRICCA) | not yet recruiting | Phase 2 | 49 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03579771 | Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT07123545 | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT07070700 | Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-02) | recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 24, 2025source: clinicaltrials